These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31023334)

  • 1. Ethical aspects of the abuse of pharmaceutical enhancements by healthy people in the context of improving cognitive functions.
    Tomažič T; Čelofiga AK
    Philos Ethics Humanit Med; 2019 Apr; 14(1):7. PubMed ID: 31023334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognition enhancers between treating and doping the mind.
    Lanni C; Lenzken SC; Pascale A; Del Vecchio I; Racchi M; Pistoia F; Govoni S
    Pharmacol Res; 2008 Mar; 57(3):196-213. PubMed ID: 18353672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.
    Savulich G; Piercy T; Brühl AB; Fox C; Suckling J; Rowe JB; O'Brien JT; Sahakian BJ
    Clin Pharmacol Ther; 2017 Feb; 101(2):170-172. PubMed ID: 27557349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.
    d'Angelo LC; Savulich G; Sahakian BJ
    Br J Pharmacol; 2017 Oct; 174(19):3257-3267. PubMed ID: 28427114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Methylphenidate for Cognitive Enhancement in Young Healthy Adults: The Clinical and Ethical Debates.
    Koren G; Korn L
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):100-102. PubMed ID: 33666399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.
    Sahakian BJ; Bruhl AB; Cook J; Killikelly C; Savulich G; Piercy T; Hafizi S; Perez J; Fernandez-Egea E; Suckling J; Jones PB
    Philos Trans R Soc Lond B Biol Sci; 2015 Sep; 370(1677):20140214. PubMed ID: 26240429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
    Sahakian BJ; Morein-Zamir S
    Lancet Psychiatry; 2015 Apr; 2(4):357-62. PubMed ID: 26360089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology.
    Cakic V
    J Med Ethics; 2009 Oct; 35(10):611-5. PubMed ID: 19793941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?
    Kapur A
    CNS Drugs; 2020 Oct; 34(10):1045-1062. PubMed ID: 32794136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuro-enhancement. Brain doping].
    Förstl H
    Nervenarzt; 2009 Jul; 80(7):840-6. PubMed ID: 19565292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.
    Mereu M; Bonci A; Newman AH; Tanda G
    Psychopharmacology (Berl); 2013 Oct; 229(3):415-34. PubMed ID: 23934211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Different Behavioral and Psychosocial Factors in the Context of Pharmaceutical Cognitive Enhancers' Misuse.
    Tomažič T; Čelofiga AK
    Healthcare (Basel); 2022 May; 10(6):. PubMed ID: 35742024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.
    Müller U; Rowe JB; Rittman T; Lewis C; Robbins TW; Sahakian BJ
    Neuropharmacology; 2013 Jan; 64(5):490-5. PubMed ID: 22820554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical enhancement and medical professionals.
    Enck GG
    Med Health Care Philos; 2014 Feb; 17(1):23-8. PubMed ID: 23922180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuro-enhancement from an addiction specialist's viewpoint].
    Soyka M
    Nervenarzt; 2009 Jul; 80(7):837-9. PubMed ID: 19543877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2013; 33(3):547-658. PubMed ID: 23042218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2013; 34(1):1-114. PubMed ID: 23186990
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.